MAGILL ASSOCIATES, LLC

Lobbying for THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES · Government and public relations consultants

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · posted Apr 1, 2026

Lobbying activity 2

Budget/Appropriations

FY 2027 appropriations for the development of a synthetic vaccine

Medical/Disease Research/Clinical Labs

FY 2027 appropriations for the development of a synthetic vaccine

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.